Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Wanbang In-licenses Diabetes Drug Rights from Sirona of Canada

publication date: Jan 27, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Wanbang Biopharma in-licensed the China rights to develop a pre-clinical diabetes drug discovered by Sirona Biochem of Canada. Wanbang will make up to $9.5 million in upfront and milestone payments plus royalties. The drug is a member of the SGLT2 class of diabetes drugs that inhibit glucose reabsorption from the kidneys. Wanbang, a division of Fosun Pharma, is active in diabetes treatments. More details....

Stock Symbols: (TSX: SBM; OTCQS: SRBCF) (SHA: 600196; HK: 02196)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



ChinaBio® Events
Shanghai, China
April 15-16, 2015

>> More events...

Partner Events

China Healthcare Investment Conference
March 31 – April 2, 2015
Shanghai, China

Asia Biotech Invest 2015
May19-21, 2015
Hong Kong, China
>> More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors